Gaithersburg’s Viela Bio Inc. began publicly trading Thursday on the Nasdaq.
The clinical-stage biotech is offering 7.9 million shares of common stock priced at $19 per share, positioning the company to raise roughly $150 million. Viela (NASDAQ: VIE) is also giving underwriters the option to buy up to an additional 1.19 million shares at the initial public offering price for 30 days.
Image: Viela Bio CEO Bing Yao and colleagues rang the opening Nasdaq bell Thursday. LIBBY GREENE